Strongbridge Biopharma plc
SEC CIK 1634432 · SBBP · last insider filing 2022-01-05
Directors (from insider filings)
| Name | Capacity as filed | Filings |
|---|---|---|
| Gill David N | Director | filed 2019 - 2021 |
| Sherman Jeffrey W | Director | filed 2018 - 2021 |
| Johnson John H | Director · Executive Chairman | filed 2018 - 2021 |
| Kollender Richard S | Director · President and CFO | filed 2018 - 2021 |
| Kong Garheng | Director | filed 2018 - 2021 |
| Steen Marten | Director | filed 2018 - 2021 |
| Steineger Hilde H | Director | filed 2018 - 2021 |
| Pauls Matthew | Director · President & CEO | filed 2018 - 2019 |
Officers (from insider filings)
| Name | Title as filed | Filings |
|---|---|---|
| Long Stephen J | Chief Legal Officer | filed 2018 - 2021 |
| Cohen Fredric J. | Chief Medical Officer | filed 2018 - 2021 |
| Wilhoit Scott L. | Chief Commercial Officer | filed 2019 - 2021 |
| Lutz Robert Matthew | Chief Financial Officer | filed 2019 - 2021 |
| Davis A Brian | Chief Financial Officer | filed 2018 - 2019 |
About this record
From the SEC's insider-transaction filings (Forms 3, 4 and 5). Every reporting director and officer carries a Commission-assigned identifier (CIK), so these footprints are identifier-verified - no name matching involved. Insiders file when they transact, so dates are filing dates: "last filed" never means "served until". This layer is not yet joined to the nonprofit register - identity joins ship only after independent review.
Source: SEC Insider Transactions Data Sets (Forms 3/4/5), US Federal Government public domain.